Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment
- 1 February 2002
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 2 (1) , 38-43
Abstract
Hemorrhagic transformation (HT) is a frequent consequence of ischemic stroke that becomes more prevalent after thrombolytic therapy. Despite concerns about safety parameters, thrombolytic drugs remain the first course of action available to clinicians for stroke management. However, recent efforts in preclinical studies have attempted to discover other drugs that can lessen the risk of hemorrhage associated with thrombolytic administration. This review focuses on three classes of pharmacologic agents that have shown some promise in animal models of stroke, and can thus be considered as possible candidates for coadministration with thrombolytics in the treatment of stroke. These include the following: 1) spin trap agents, such as α-phenyl-N-t-butylnitrone (PBN) that scavenge free radicals; 2) matrix metalloproteinase (MMP) inhibitors, such as BB-94, that prevent membrane and vessel remodeling following ischemia; and 3) the novel glycoprotein (GP) IIb/IIIa platelet receptor antagonist SM-20302. Although these drugs affect different mechanisms, the common denominator seemed to be their effectiveness in reducing the incidence of hemorrhage in response to thrombolytic infusion following an embolic stroke.Keywords
This publication has 80 references indexed in Scilit:
- Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen ActivatorStroke, 2001
- Pharmacological Effects of the Spin Trap AgentsN-t-Butyl-Phenylnitrone (PBN) and 2,2,6,6-Tetramethylpiperidine-N-Oxyl (TEMPO) in a Rabbit Thromboembolic Stroke ModelStroke, 2001
- Reducing Bleeding Complications After Thrombolytic Therapy for StrokeCNS Drugs, 2001
- Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic StrokeStroke, 2000
- Extracellular matrix degradation by metalloproteinases and central nervous system diseasesMolecular Neurobiology, 1999
- Free radical spin traps as adjuncts for the prevention and treatment of diseaseMedical Hypotheses, 1999
- Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in RatsStroke, 1998
- Tumor Necrosis Factor-αStroke, 1997
- Relaxed Specificity of Matrix Metalloproteinases (MMPS) and TIMP Insensitivity of Tumor Necrosis Factor-α (TNF-α) Production Suggest the Major TNF-α Converting Enzyme Is Not an MMPBiochemical and Biophysical Research Communications, 1996
- Calcium and Ischemic InjuryNew England Journal of Medicine, 1986